Cash from Operations (TTM) Chart

View Cash from Operations (TTM) for PHIO.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Cash from Operations (TTM) Chart
Start Trial

Historical Cash from Operations (TTM) Data

View and export this data back to 2012. Start Trial.
Date Value
June 30, 2026 -12.20M
March 31, 2026 -10.71M
December 31, 2025 -7.979M
September 30, 2025 -7.271M
June 30, 2025 -7.139M
March 31, 2025 -6.376M
December 31, 2024 -7.112M
September 30, 2024 -8.111M
June 30, 2024 -9.058M
March 31, 2024 -10.05M
December 31, 2023 -10.75M
September 30, 2023 -11.08M
June 30, 2023 -11.71M
March 31, 2023 -11.37M
December 31, 2022 -12.13M
September 30, 2022 -11.90M
June 30, 2022 -11.47M
March 31, 2022 -12.29M
December 31, 2021 -11.86M
September 30, 2021 -12.01M
June 30, 2021 -10.88M
March 31, 2021 -9.659M
December 31, 2020 -8.802M
September 30, 2020 -8.725M
June 30, 2020 -8.745M
Date Value
March 31, 2020 -8.646M
December 31, 2019 -8.645M
September 30, 2019 -7.845M
June 30, 2019 -7.861M
March 31, 2019 -7.788M
December 31, 2018 -7.52M
September 30, 2018 -7.975M
June 30, 2018 -8.165M
March 31, 2018 -8.622M
December 31, 2017 -9.514M
September 30, 2017 -8.685M
June 30, 2017 -8.091M
March 31, 2017 -7.634M
December 31, 2016 -7.76M
September 30, 2016 -7.97M
June 30, 2016 -8.33M
March 31, 2016 -8.27M
December 31, 2015 -7.317M
September 30, 2015 -7.33M
June 30, 2015 -7.133M
March 31, 2015 -7.35M
December 31, 2014 -7.758M
September 30, 2014 -7.565M
June 30, 2014 -7.524M
March 31, 2014 -7.563M

Cash From Operations Definition

Represents the net cash flow from the company's business operations.

Read full definition.

Cash from Operations (TTM) Range, Past 5 Years

View Cash from Operations (TTM) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Cash from Operations (TTM) Benchmarks

View Cash from Operations (TTM) Benchmarks
Start Trial
Imunon, Inc. -15.11M
Agenus, Inc. -98.50M
Amgen, Inc. 12.48B
Anika Therapeutics, Inc. 5.977M
BioCryst Pharmaceuticals, Inc. 358.99M